Come on, come on! Hengrui third quarter report!

Today, Hengrui announced its third quarter report of this year, with revenue of 16.9 billion yuan (+ 36.01%); net profit attributable to shareholders of listed companies of 3.7 billion yuan (+ 28.26%); net profit attributable to shareholders of listed companies deducting non recurring profit and loss of 3.5 billion yuan (+ 27.25%) R & D investment reached 2.9 billion, up 66.97% year on year On the same day, the notice of clinical trial of apatinib mesylate tablets of Hengrui was published on the Internet, and the State Food and Drug Administration agreed to carry out the clinical study of apatinib mesylate combined with etoposide capsule in the treatment of recurrent ovarian cancer with platinum treatment failure Basic drug information: Name: apatinib mesylate tablet type: tablet specification: 0.25g0.375g application item: clinical trial applicant: Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd acceptance No.: cxhl1900286, cxhl1900287 Apatinib mesylate is a small molecule tyrosine kinase inhibitor independently developed by Hengrui medicine It can selectively inhibit the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR-2), thus inhibiting tumor angiogenesis and tumor growth In December 2014, apatinib mesylate was approved for the treatment of advanced gastric cancer with second-line chemotherapy failure Through inquiry, there are solafeinib, sunitinib and other similar products of apatinib mesylate at home and abroad, which have been approved for marketing Solafeinib was developed by Bayer company and approved to be listed in the United States as early as 2005; sunitinib was developed by Pfizer company and approved to be listed in the United States as early as 2006 In 2018, the sales volume of apatinib mesylate was about 1.7 billion yuan Up to now, the R & D cost of relevant projects has been about 281.46 million yuan According to the requirements of the relevant laws and regulations of drug registration in China, after the drug obtains the notice of clinical trial, it is still necessary to carry out the clinical trial and the drug can be produced and put on the market after being reviewed and approved by the State Food and drug administration Editor in charge: penicillin statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.